IMVT · ISSUER CIK 1764013
Immunovant, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 5 Immunovant, Inc. insiders reported $0.00 of open-market purchases and $735K of sales on SEC Form 4.
↗5 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 1 of 8 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$735KInsider selling
−$735KNet open-market
Oct 23, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 202616:55 | Oct 21, 2026 | IMVT | Chief Technology Officer | S · Sell | $28.94 | −2,595 | 198,937 | -1% | −$75K | ||
| Oct 9, 202617:05 | Oct 7, 2026 | IMVT | Chief Technology Officer | S · Sell | $32.06 | −3,809 | 201,532 | -2% | −$122K | ||
| Oct 9, 202617:05 | Oct 7, 2026 | IMVT | Chief Legal Officer | S · Sell | $32.06 | −1,327 | 175,218 | -1% | −$43K | ||
| Oct 9, 202617:04 | Oct 7, 2026 | IMVT | Chief Operating Officer | S · Sell | $32.06 | −2,241 | 217,060 | -1% | −$72K | ||
| Oct 5, 202619:42 | Oct 2, 2026 | IMVT | Chief Executive Officer, Director | S · Sell | $34.11 | −3,506 | 257,075 | -1% | −$120K | ||
| Oct 5, 202619:42 | Oct 1, 2026 | IMVT | Chief Executive Officer, Director | M · Exercise | $14.46 | +92,187 | 346,467 | +36% | $1.3M | ||
| Oct 5, 202619:42 | Oct 1, 2026 | IMVT | Chief Executive Officer, Director | D · To issuer | $33.65 | −85,886 | 260,581 | -25% | $2.9M | ||
| Sep 25, 202616:05 | Sep 23, 2026 | IMVT | Chief Legal Officer | S · Sell | $36.36 | −2,846 | 176,545 | -2% | −$103K | ||
| Aug 28, 202616:27 | Aug 28, 2026 | IMVT | Director | S · Sell10b5-1 | $43.27 | −1,500 | 116,731 | -1% | −$65K | ||
| Aug 28, 202616:27 | Aug 28, 2026 | IMVT | Director | M · Exercise10b5-1 | $8.43 | +1,500 | 118,231 | +1% | $13K | ||
| Aug 21, 202616:03 | Aug 20, 2026 | IMVT | Chief Operating Officer | S · Sell | $44.16 | −3,056 | 219,301 | -1% | −$135K |